Prospective, Unmasked Evaluation of the iStent® Inject System for Open-Angle Glaucoma: Synergy Trial
Open Access
- 23 January 2014
- journal article
- clinical trial
- Published by Springer Nature in Advances in Therapy
- Vol. 31 (2) , 189-201
Abstract
Introduction Micro-invasive glaucoma surgical implantation of trabecular micro-bypass stents, previously shown to be safe and effective for open-angle glaucoma (OAG) subjects during cataract surgery, was considered for evaluation as a sole procedure. The aim of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy after ab interno implantation of two Glaukos Trabecular Micro-Bypass iStent inject second generation devices in subjects with OAG. This study was performed at sites in France, Germany, Italy, Republic of Armenia, and Spain. Methods In this pan-European, multi-center prospective, post-market, unmasked study, 99 patients with OAG on at least two topical ocular hypotensive medications who required additional IOP lowering to control glaucoma disease underwent implantation of two GTS400 stents in a stand-alone procedure. Patients were qualified if they presented with preoperative mean IOP between 22 and 38 mmHg after medication washout. Postoperatively, subjects were assessed at Day 1, Months 1, 3, 6, 7, 9, and 12. IOP, medication use and safety were assessed at each visit. Results Sixty-six percent of subjects achieved IOP ≤18 mmHg at 12 months without medication, and 81% of subjects achieved Month 12 IOP ≤ 18 mmHg with either a single medication or no medication. Mean baseline washout IOP values decreased by 10.2 mmHg or 39.7% from 26.3 (SD 3.5) mmHg to 15.7 (SD 3.7) mmHg at Month 12. Mean IOP at 12 months was 14.7 (SD 3.1) mmHg in subjects not using ocular hypotensive medications. Reduction from preoperative medication burden was achieved in 86.9% of patients, including 15.2% with reduction of one medication and 71.7% with reduction of two or more medications. Postoperative complications occurred at a low rate and resolved without persistent effects. Conclusion In this series, implantation of two trabecular micro-bypass second generation stents in subjects with OAG resulted in IOP and medication reduction and favorable safety outcomes.Keywords
This publication has 14 references indexed in Scilit:
- Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataractBritish Journal of Ophthalmology, 2013
- Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucomaJournal of Cataract & Refractive Surgery, 2012
- Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: Two-year follow-upJournal of Cataract & Refractive Surgery, 2012
- Second-generation Trabecular Meshwork Bypass Stent (iStent inject) Increases Outflow Facility in Cultured Human Anterior SegmentsAmerican Journal of Ophthalmology, 2012
- Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term studyBritish Journal of Ophthalmology, 2012
- Global data on visual impairment in the year 2002.2004
- Trabecular bypass stents decrease intraocular pressure in cultured human anterior segmentsAmerican Journal of Ophthalmology, 2004
- Outflow resistance of enucleated human eyes at two different perfusion pressures and different extents of trabeculotomyCurrent Eye Research, 1989
- Pressure-Dependent Changes in Structures of the Aqueous Outflow System of Human and Monkey EyesAmerican Journal of Ophthalmology, 1973
- Experimental Aqueous Perfusion in Enucleated Human EyesArchives of Ophthalmology (1950), 1963